DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid … Read more
AlzeCure Pharma has found a partner for its Alzheimer’s program, and the numbers attached to the deal are eye-catching, though not all of them in the way the headline suggests. The Swedish biotech said on July 1 that it has signed an out-licensing and collaboration agreement with QuantumCell, a Danish “tech-enabled” biotech, handing over global … Read more
Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
DealFlow Weekly — Wk 26 · 2026 · Synopulse DealFlow WeeklyOn a deep pine background, a faint network of the week’s thirty-five deals fades in while a gold deal line draws across and five gold molecular-ring nodes bloom along it, beside the DealFlow Weekly wordmark and the tagline a weekly readout from Synopulse. SYNOPULSE — … Read more
Pfizer has signed one of the year’s largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China’s Innovent Biologics.
February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
Novartis and Relation Therapeutics have struck a $1.7 billion collaboration to discover new immuno-dermatology drug targets using Relation’s AI-powered “Lab-in-the-Loop” platform.
Pfizer has forged an exclusive global partnership with YaoPharma to develop and commercialize YP05002, a small-molecule GLP-1 agonist for chronic weight management.